BillionToOne Is Solving One of Biotech’s Hardest Problems
BillionToOne has cracked one of biotech's hardest problems: detecting rare genetic signals in blood samples by solving a "needle in a haystack" challenge of finding one abnormal base pair among 3 billion. Founded by two PhD students in 2017, the company went from a half lab bench and $300K to processing 600,000+ tests annually and a $4B+ public valuation by building a step-by-step strategy—starting with prenatal genetic testing before moving to cancer detection—that demonstrates how resource constraints can drive innovation and how founders can scale from idea to market dominance in a regulated industry.
Key takeaways
- • Start with the least capital-intensive problem you can solve in your market, achieve commercial traction, then use those resources to tackle harder, larger problems—this three-step approach (prenatal testing → late-stage cancer detection → early-stage cancer screening) allowed BillionToOne to avoid raising $1B+ upfront and build credibility with each win.
- • Solve the sales problem before scaling operations: BillionToOne had one physician using their test 2 months post-launch; the founders responded by hiring 5 additional sales reps in 3 weeks and pivoting to patient-to-physician marketing, which worked because "when we talk with patients, we can convince them" to request the test from their doctors.
- • Recruit interdisciplinary scientists (not just interdisciplinary teams) who can bridge chemistry, biology, and data science within a single person—BillionToOne's key insight that fetal and tumor DNA amplification creates noise that can be mathematically removed required scientists who understood both the lab chemistry and computational solutions simultaneously.
- • Add synthetic DNA markers to blood samples *before* amplification begins so you can measure exactly how much noise the amplification process introduces, then subtract it from the final data using machine learning—this transforms a "difficult biology problem to almost a simple mathematical problem" that competitors couldn't solve.
- • Structure R&D as internal startups: Create small teams (2-3 research associates + a principal investigator) who report directly to founders, own end-to-end product development, and iterate weekly without bureaucratic friction—this "many startups within the larger company" model accelerates product cycles and keeps top talent engaged even after the company goes public.
- • The holy grail in cancer detection is screening healthy populations for early-stage cancer before symptoms appear; this requires solving the same technical problem as detecting microscopic residual disease in post-surgery patients, so BillionToOne structured their roadmap to reach the harder problem only after proving the technology on easier use cases first.
Mentioned (3)
More from these creators
François Chollet: Why Scaling Alone Isn’t Enough for AGI
Inside The Startup Reinventing America’s Trillion Dollar Chemical Industry
India’s Fastest Growing AI Startup
The Future Of Brain-Computer Interfaces
Common Mistakes With Vibe Coded Websites
The Powerful Alternative To Fine-Tuning